Exclusive Drug Patent Licensing Deals Face New Scrutiny By FTC/DOJ
This article was originally published in The Pink Sheet Daily
Executive Summary
The Federal Trade Commission finalized a proposed rule that requires pharma companies to report certain transactions transferring exclusive patent rights; PhRMA says annual costs will go far beyond FTC’s $1.2 million estimate.